

Special Issue

New Advances in Kaposi's Sarcoma-Associated Herpesvirus Research

Message from the Guest Editor

Discovered in 1994, Kaposi's sarcoma-associated herpesvirus (KSHV) is one of seven oncogenic viruses and one of two herpesviruses associated with human cancer. Unlike small DNA tumour viruses, KSHV is not constrained by genetic economy. With over 85 protein-coding regions (that we know of), this herpesvirus is a master manipulator. KSHV deregulates antiviral responses, hijacks stress signaling and metabolic pathways, elicits aberrant cell proliferation and induces angiogenesis while reprogramming immune responses so that the virus can persist in a chronic latent state. Such complex virus-host interplay must be understood in molecular detail if we seek to intervene and treat these chronic infections without causing harm. In addition, as has so often been the case in the past, understanding how viruses manipulate and subvert our host defenses provides a window into the complexities of immune system regulation.

Guest Editor

Dr. Jennifer Corcoran

Department of Microbiology, Immunology and Infectious Diseases,
University of Calgary, Calgary, AB, Canada

Deadline for manuscript submissions

closed (31 October 2021)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/42206

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).